Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise
Scholar Rock’s apitegromab could become the first muscle-targeted SMA therapy by September 2026, but manufacturing setbacks and a…
Equity Eagle NASDAQ
Scholar Rock Holding Corp
SRRK
1 story
$4.9B Market cap · 2026-10-20
Equity Eagle 